A 24 mg dose (IV bolus) of a new medication, LIU323, is administered to a human subject, and plasma and urine samples are collected for 60 hours post-dose. Your data analysis finds that the elimination half-life for LIU323 is 9.1 hr and the volume of distribution is 54.4 L. LIU323 is 80 % bound to plasma proteins. The cumulative amount of LIU323 excreted into the urine (based on a 60 hr total urine collection) was 14.0 mg. The estimated GFR in this subject was 80 ml/min.